http://www.reportlinker.com/p0849622/Commercializing-Pancreatic-Cancer-Drugs-The-Faster-Route-to-Consider-Your-Options-and-Position-of-Others.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
This report will excel your competitive awareness and decrease your decision making time in managing pancreatic cancer drug development. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.
This report comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in pancreatic cancer. BioSeeker has applied its unique drug assessment methodology to stratify the pancreatic cancer drug pipeline and discern the level of competition in fine detail.
Major Findings from this report:
* The identified competitive landscape of pancreatic cancer drugs is split between the half which have unique drug target strategies and the other half which have head-to-head target competing drugs in 37 different clusters. The latter has a competing ratio which is more than two times higher than the comparable average of the pancreatic cancer drugs in general.
* Nine out of every ten drug target strategies in Phase III and Phase II development are new to pancreatic cancer drugs.
* The greatest number of new target strategies are found in Phase II (37%) and Phase I (18%) development.
* Small molecules, Antibodies and Reformulated drugs are the dominating compound strategies of pancreatic cancer drugs, which represent almost 80% of the entire pipeline.
* Besides Reformulated drugs, it is Protein and Peptide based pancreatic cancer drugs that have the highest cross-over of drug target strategies with other compound strategies, especially with that of Antibodies.
* The highest number of described drug target strategies of pancreatic cancer drugs belongs to Pfizer, Hoffmann-La Roche, Novartis and AstraZeneca.
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:
* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
* Supporting development of integrative molecule, pathway and disease area strategies
* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any pancreatic cancer drug in cancer to ensure that the optimal market conditions exist by the time the product is commercialized.
1 Executive Summary 32 About Cancer Highlights™ 52.1 Cancer Focus Areas 52.2 Subscribe Today and Start Saving 62.2.1 Type of License 62.3 Additional Information 62.4 BioSeeker Group's Oncology Team 63 Methodology 73.1 Cancer Highlights'™ Five Pillar Drug Assessment 74 Table of Contents 94.1 List of Figures 194.2 List of Tables 195 Introduction 275.1 The Scope of this Report 275.2 Definitions 305.3 Abbreviations 306 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment 316.1 Drug Repositioning in Oncology 316.2 Introduction to Targets of Pancreatic Cancer Drugs 326.2.1 Carboxy-lyase Activity Targets 396.2.2 Catalytic Activity Targets 406.2.3 Cell Adhesion Molecule Activity Targets 516.2.4 Chaperone Activity Targets 596.2.5 Cofactor Binding Targets 606.2.6 Cysteine-type Peptidase Activity Targets 626.2.7 Cytokine Activity Targets 696.2.8 DNA Binding Targets 756.2.9 DNA Repair Protein Targets 776.2.10 DNA Topoisomerase Activity Targets 806.2.11 DNA-directed DNA Polymerase Activity Targets 856.2.12 Extracellular Ligand-gated Ion Channel Activity Targets 926.2.13 Extracellular Matrix Structural Constituent Targets 946.2.14 G-protein Coupled Receptor Activity Targets 986.2.15 Growth Factor Activity Targets 1086.2.16 GTPase Activity Targets 1146.2.17 Hormone Activity Targets 1236.2.18 Hydrolase Activity Targets 1246.2.19 Ion Channel Activity Targets 1256.2.20 Kinase Activity Targets 1266.2.21 Kinase Binding Targets 1386.2.22 Kinase Regulator Activity Targets 1396.2.23 Ligand-dependent Nuclear Receptor Activity Targets 1436.2.24 Ligase Activity Targets 1446.2.25 Lipase activity 1506.2.26 Lipid kinase activity 1516.2.27 Lipid Phosphatase Activity Targets 1546.2.28 Molecular Function Unknown Targets 1556.2.29 Motor Activity Targets 1656.2.30 Oxidoreductase Activity Targets 1676.2.31 Peptidase Activity Targets 1736.2.32 Peptide Hormone Targets 1836.2.33 Peroxidase Activity Targets 1856.2.34 Protein Binding Targets 1866.2.35 Protein Serine/Threonine Kinase Activity Targets 1886.2.36 Protein Threonine/Tyrosine Kinase Activity Targets 2136.2.37 Protein Tyrosine Phosphatase Activity Targets 2186.2.38 Protein-tyrosine Kinase Activity Targets 2266.2.39 Receptor Activity Targets 2376.2.40 Receptor Binding Targets 2556.2.41 Receptor Signaling Complex Scaffold Activity Targets 2606.2.42 RNA Binding Targets 2646.2.43 RNA-directed DNA Polymerase Activity Targets 2656.2.44 Serine-type Peptidase Activity Targets 2666.2.45 Structural Constituent of Cytoskeleton Targets 2716.2.46 Structural Molecule Activity Targets 2736.2.47 Transcription Factor Activity Targets 2746.2.48 Transcription Regulator Activity Targets 2926.2.49 Transferase Activity Targets 2986.2.50 Translation Regulator Activity Targets 2996.2.51 Transmembrane Receptor Activity Targets 3016.2.52 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 3046.2.53 Transporter Activity Targets 3406.2.54 Unclassified Targets 3456.2.55 Voltage-gated Ion Channel Activity Targets 3466.2.56 Other Targets 3476.3 The Cancer Genome Project and Targets of Pancreatic Cancer Drugs 3486.3.1 Targets of Pancreatic Cancer Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 3486.4 Pancreatic Cancer Therapeutics is Stimulated by Available Structure Data on Targets 3546.5 Target-Target Interactions among Identified Targets of Pancreatic Cancer Drugs 3586.6 The Drug-Target Competitive Landscape 3626.7 Protein Expression Levels of Identified Targets of Pancreatic Cancer Drugs 3666.8 Pathway Assessment of Pancreatic Cancer Drugs 3696.8.1 Tools for Analysis of Cancer Pathways 3706.8.2 Pathway Assessment 3717 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development 4237.1 Registered to Marketed: New and Unique Drug Target Strategies of Pancreatic Cancer Drugs 4257.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Pancreatic Cancer Drugs 4267.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Pancreatic Cancer Drugs 4287.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Pancreatic Cancer Drugs 4337.5 Preclinical Development: New and Unique Drug Target Strategies of Pancreatic Cancer Drugs 4367.6 Drug Target Strategies of Suspended or Terminated Pancreatic Cancer Drugs 4387.7 Target Strategy Development Profiles of Pancreatic Cancer Drugs 4407.7.1 Marketed 4447.7.2 Phase III 4477.7.3 Phase II 4627.7.4 Phase I 5227.7.5 Preclinical 5527.7.6 Suspended 5757.7.7 Ceased 5777.8 The Competition Through Close Mechanistic Approximation of Pancreatic Cancer Drugs 6098 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy 6138.1 Small Molecules 6158.1.1 Background 6158.1.2 Target Strategies of Small Molecule Drugs 6168.2 Peptide & Protein Drugs 6248.2.1 Background 6248.2.2 Target Strategies of Peptide and Protein Drugs 6258.3 Antibodies 6308.3.1 Background 6308.3.2 Target Strategies of Antibody Drugs 6308.4 Nucleic Acid Therapies 6348.4.1 Background 6348.4.2 Target Strategies of Nucleic Acid Drugs 6358.5 Cell & Gene Therapy 6378.5.1 Background 6378.5.2 Target Strategies of Cell and Gene Therapy Drugs 6388.6 Drug Delivery and Nanotechnology 6428.6.1 Background 6428.6.2 Target Strategies of Reformulated Drugs 6428.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets 6459 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator 6529.1 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 6569.2 Company Facts and Ranking 6589.3 Competitive Fall-Out Assessment 6669.4 AB Science 6689.5 Abbott 6709.6 Active Biotech 6739.7 Advantagene 6759.8 Advaxis 6789.9 AEgera 6819.10 Aida Pharmaceuticals 6839.11 Amgen 6859.12 Antisense Pharma 6909.13 Anza Therapeutics 6929.14 Apogee Biotechnology 6949.15 Apotex 6969.16 Ardea Biosciences 6989.17 Ariad 7019.18 ArQule 7039.19 Array BioPharma 7059.20 Astellas 7099.21 AstraZeneca 7149.22 AVEO 7199.23 AVI BioPharma 7219.24 Bayer 7249.25 Betapharma 7279.26 Biogen Idec 7309.27 Bionovo 7339.28 BioNumerik 7359.29 BioSante 7389.30 Boehringer Ingelheim 7409.31 Bristol-Myers Squibb 7429.32 BTG 7479.33 Calando Pharmaceuticals 7519.34 Cancer Advances 7539.35 Cancer Research Technology 7559.36 Celera 7579.37 Celgene 7599.38 Cell Therapeutics 7639.39 Celldex Therapeutics 7669.40 Celsion 7699.41 Celtic Pharma 7729.42 Center of Molecular Immunology 7749.43 CG Therapeutics 7779.44 CompleGen 7809.45 Cornerstone Pharmaceuticals 7829.46 CritiTech 7849.47 Curaxis 7879.48 Curis 7899.49 Cyclacel 7919.50 Cylene Pharmaceuticals 7939.51 Cynvec 7959.52 CytImmune Sciences 7979.53 Cytokinetics 7999.54 CytRx 8019.55 Daiichi Sankyo 8049.56 Dara Biosciences 8099.57 EGEN Inc 8119.58 Eisai 8139.59 Eli Lilly 8189.60 EntreMed 8239.61 Epeius Biotechnologies 8259.62 EpiCept 8279.63 Esperance Pharmaceuticals 8309.64 Exelixis 8329.65 FibroGen 8349.66 Galectin Therapeutics 8369.67 Genta 8399.68 GenVec 8419.69 Geron 8439.70 GlaxoSmithKline 8459.71 GlycoGenesys 8509.72 Hoffmann-La Roche 8529.73 Human Genome Sciences 8589.74 ImmunoCellular Therapeutics 8609.75 ImmunoGen 8629.76 Immunomedics 8659.77 ImmuPharma 8699.78 Immutep 8719.79 Innate Pharma 8739.80 Innovive 8759.81 Insmed 8789.82 Insys Therapeutics 8819.83 Introgen Therapeutics 8879.84 Ipsen 8899.85 Johnson & Johnson 8929.86 Kadmon 8949.87 Kyowa Hakko Kirin 8969.88 Leo 8989.89 MBiotec 9009.90 Meda 9029.91 MediGene 9049.92 Medisyn Technologies 9089.93 Merck & Co 9109.94 Merck KGaA 9149.95 Merrimack 9189.96 Mersana Therapeutics 9219.97 MethylGene 9249.98 Micromet 9269.99 Nektar Therapeutics 9289.100 Nereus Pharmaceuticals 9319.101 Nippon Kayaku 9339.102 Nippon Shinyaku 9369.103 Non-industrial Source 9389.104 Novacea 9419.105 NovaLead 9449.106 Novartis 9479.107 Novogen 9539.108 OncoMed 9559.109 OncoTherapy Science 9579.110 Oncothyreon 9599.111 Oncozyme Pharma 9619.112 Oxford BioMedica 9639.113 OXiGENE 9659.114 Paladin Labs 9679.115 PanaGin 9709.116 Patrys 9729.117 Pepscan Therapeutics 9749.118 Pfizer 9769.119 Pharmacyclics 9839.120 PharmaMar 9859.121 Pharmexa 9879.122 Pierre Fabre 9909.123 Piramal 9939.124 ProMetic Life Sciences 9959.125 Protgen 9979.126 Ras Therapeutics 9999.127 Reata Pharmaceuticals 10019.128 Regeneron 10039.129 Regulon 10059.130 RESprotect 10079.131 Rexahn 10099.132 Rigel 10129.133 Rottapharm Madaus 10149.134 Samyang 10179.135 Sanofi 10219.136 Santaris Pharma 10269.137 Shire 10289.138 SuperGen 10309.139 Taiho 10349.140 Takeda 10389.141 Talon Therapeutics 10409.142 Tapestry Pharmaceuticals 10439.143 Tau Therapeutics 10469.144 Teva 10489.145 Thallion Pharmaceuticals 10509.146 Therion Biologics 10529.147 Titan Pharmaceuticals 10549.148 TopoTarget 10579.149 Tragara Pharmaceuticals 10609.150 Trion Pharma 10629.151 UMN Pharma 10649.152 VaxOnco 10669.153 Vertex Pharmaceuticals 10689.154 Vion Pharmaceuticals 10709.155 VioQuest 10729.156 ViroMed 10759.157 Wilex 10789.158 Xerion 10809.159 Yakult Honsha 10829.160 YM BioSciences 10859.161 Zeria 1088Disclaimer 109010 Drug Index 109111 Company Index 1098
Be the first to review this article
